|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N07XX12
|
|
gptkbp:CASNumber
|
1673727-01-4
|
|
gptkbp:chemicalFormula
|
C528H658N188O320P26S26
|
|
gptkbp:cost
|
high
|
|
gptkbp:developer
|
gptkb:Alnylam_Pharmaceuticals
|
|
gptkbp:drugClass
|
small interfering RNA
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
lipid nanoparticle
|
|
gptkbp:genericName
|
gptkb:patisiran
|
|
gptkbp:halfLife
|
3-5 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Onpattro
|
|
gptkbp:indication
|
polyneuropathy of hereditary transthyretin-mediated amyloidosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits transthyretin synthesis
|
|
gptkbp:pregnancyCategory
|
not assigned
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
fatigue
flushing
infusion-related reactions
upper respiratory tract infections
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:UNII
|
Q5D430J2XV
|
|
gptkbp:usedFor
|
hereditary transthyretin-mediated amyloidosis
|
|
gptkbp:bfsParent
|
gptkb:Alnylam_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|